Article Details
Retrieved on: 2021-04-12 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Joe Moscato, CEO of NuGenerex Immuno-Oncology (NGIO) and Generex Biotechnology (GNBT) said, “We have made significant progress in the ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here